Drug Approval | December 26, 2025
Japan nod to Dupixent for children with severe asthma
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The decision is based on robust clinical evidence from the VOYAGE and EXCURSION studies
The new single-use commercial facility will be among India’s largest, featuring advanced technologies to produce high-quality biologics and specialty pharmaceuticals
The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The opening of our 1000th pharmacy in Karnataka marks an important step
U.S. and Canada transaction supports continued access to RADICAVA for people living with ALS
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
If approved, imlifidase has the potential to transform the kidney transplant landscape by enabling highly sensitized patients to also have access to a potentially life-changing kidney transplant
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
